| Product development partnerships have revived antimalarial drug development, and a variety of target candidate and product profiles have been defined to support control and elimination goals |
| New agents (arterolane, cipargamin, KAF156) on the horizon show potential to replace failing artemisinin combination therapies as part of novel combinations |
| The loss of front-line therapies to resistance has stimulated a reappraisal of the current approach to combination therapy for malaria, with consideration of a switch from dual to triple drug combinations |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.